SCHEMBL3518154

SCHEMBL3518154

O=C(O)c1c(O)c(-c2ccc(F)c(F)c2)cc2nc(-c3cccs3)cnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.41
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
GAA P10253 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
HPGD P15428 2/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPK10 P53779 1/20 0.39
ERN1 O75460 1/20 0.38
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
PRNP P04156 1/20 0.37
PPARG P37231 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
KMO O15229 2/20 0.36
TOP1 P11387 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521131 0.93 RXFP1 (0.40) RXFP1KDM4EALDH1A1GAANPC1
SCHEMBL3520062 0.88 EGLN3 (0.49) RXFP1KDM4EALDH1A1GAANPC1
SCHEMBL3517411 0.88 KDM4E (0.48) RXFP1KDM4EALDH1A1GAANPC1
SCHEMBL3522596 0.86 KMO (0.45) ALDH1A1GAAKMOTOP1EIF4E
SCHEMBL3519547 0.82 KDM4E (0.42) RXFP1KDM4EALDH1A1GAANPC1
SCHEMBL3521733 0.82 TOP1 (0.42) KMOTOP1FYN
SCHEMBL3519757 0.82 EGLN3 (0.38) KDM4EALDH1A1GAANPC1RAB9A
SCHEMBL3520213 0.81 MEN1 (0.42) KDM4EALDH1A1GAANPC1RAB9A
SCHEMBL3519157 0.81 EGLN3 (0.47) KDM4EALDH1A1GAAERN1MEN1
SCHEMBL3519937 0.79 RXFP1 (0.47) RXFP1KDM4EALDH1A1GAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 RXFP1 1151/4885KDM4E 176/4885ALDH1A1 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.